<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03450876</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-483</org_study_id>
    <nct_id>NCT03450876</nct_id>
  </id_info>
  <brief_title>Long Term Quality of Life in Melanoma Patients in Netherlands</brief_title>
  <official_title>A Prospective Multicenter Cohort Study of Late Physical Psychological and Social Effects in Patients Treated With Ipilimumab for Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      Study of late physical, psychological and social effects in patients treated with ipilimumab
      for advanced (stage IV or unresectable stage III) melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">May 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ C30)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>14-item questionnaire assesses symptoms of mood disturbance, yielding separate scale scores for anxiety and depression, as well as a total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Fatigue Inventory (MFI)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Worry Scale (CWS)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>8-item questionnaire will be used to assess the prevalence of cancer-specific distress in melanoma survivors and in healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer Quality Of Life (EORTC QLQ) module for sexual health</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>Sexual health will be assessed with the European Organisation for Research and Treatment of Cancer Quality Of Life (EORTC QLQ) module for sexual health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-Melanoma questionnaire (FACT-M)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>51-item measurement of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQOL-5D (EQ-5D) survivors</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>Generic health status will be assessed with the EuroQOL-5D (EQ-5D) survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Cancer Questionnaire (IOCv2)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>81 items that present statements regarding specific impacts of cancer to which respondents indicate their level of agreement from 1 (strongly disagree) to 5 (strongly agree). Seventy items apply to all survivors, 3 to currently employed respondents, 4 to respondents not currently partnered, and 4 to currently partnered respondents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Ability Index questionnaire (WAI)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>13-item questionnaire developed to obtain survivors' experiences with return to work and work performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC information module (EORTC QLQINFO25)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>Information needs will be assessed with the EORTC information module (EORTC QLQINFO25)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">468</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 to &lt; 36 months post-ipilimumab treatment</arm_group_label>
    <description>24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>≥ 36 to &lt; 48 months post-ipilimumab treatment</arm_group_label>
    <description>36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>≥ 48 months post-ipilimumab treatment</arm_group_label>
    <description>Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>24 to &lt; 36 months post-ipilimumab treatment</arm_group_label>
    <arm_group_label>≥ 36 to &lt; 48 months post-ipilimumab treatment</arm_group_label>
    <arm_group_label>≥ 48 months post-ipilimumab treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced melanoma who survived at least 2 years and were treated with
        ipilimumab between 2011 and 2015 in one of the specified melanoma centers in the
        Netherlands.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria-

          -  Patient population: Adults ≥ 18 years of age at diagnosis, diagnosed with
             histologically confirmed advanced (stage IV or unresectable stage III) melanoma, who
             have received at least one course of ipilimumab treatment (first, second, or second
             plus line; routine practice or study treatment) in one of the specified treatment
             centers, and who have survived at least 2 years after (completion of) ipilimumab
             treatment (measured from last ipilimumab administration)

          -  Matched healthy control population: Individuals without melanoma (stage III or IV)
             diagnosis that have been included in the PROFILES cohort

        Exclusion Criteria

          -  Insufficient understanding of the Dutch language

          -  Other anticancer treatment after ipilimumab or during study entry

          -  Disease recurrence during the study

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

